Iloprost Rafarm

Iloprost, the active ingredient in Iloprost Rafarm, is a prostacyclin analog presented as an inhalation solution for inhalation use. It is employed in the management of pulmonary arterial hypertension and in the treatment of digital ulcers associated with systemic sclerosis, helping to improve vascular tone and promote ulcer healing.

GNH USA supplies Iloprost Rafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Iloprost, a prostacyclin analog, targets the prostacyclin (IP) receptor to produce vasodilation and inhibit platelet aggregation, making it useful in diseases characterized by pulmonary vascular constriction and microvascular injury.

Pulmonary arterial hypertension: reduces pulmonary vascular resistance, improves hemodynamics, and enhances exercise tolerance and functional class. Digital ulcers associated with systemic sclerosis: increases blood flow to ischemic skin, accelerates ulcer closure, and lowers the incidence of new ulcer development.

Iloprost may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough - Throat irritation - Headache - Flushing

Serious or Rare Side Effects: - Severe hypotension - Pulmonary edema - Significant bleeding - Bronchospasm

When prescribing Iloprost, clinicians should consider several safety measures to minimize risk. - Monitor blood pressure: check for hypotension before and during therapy. - Assess bleeding risk: evaluate concomitant anticoagulant use and history of hemorrhage. - Evaluate pulmonary function: watch for bronchospasm in patients with reactive airway disease. - Avoid use in recent hemoptysis: contraindicated in active pulmonary bleeding. - Use with caution in hepatic impairment: adjust therapy based on liver function. - Store at room temperature: keep in original container, protect from moisture and light.

Iloprost can interact with other medicines, altering its vasodilatory effect or bleeding risk.

Major Interactions (Avoid): - Concomitant potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Anticoagulants (e.g., warfarin, heparin): increase risk of bleeding. - Other prostacyclin analogs: additive vasodilatory effects. - Endothelin receptor antagonists: may enhance pulmonary vasodilation excessively.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may potentiate blood pressure lowering. - Phosphodiesterase‑5 inhibitors: could increase pulmonary vasodilation. - NSAIDs: may affect platelet function and increase bleeding tendency.